专题：Liver Diseases and Immunity

This cluster of papers focuses on the diagnosis, management, epidemiology, and genetic factors of autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis. It also covers topics such as liver transplantation, immunosuppressive therapy, and the pathogenesis of these liver diseases.
最新文献
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

article Full Text OpenAlex

Hepatocyte TonEBP promotes metabolic stress-induced hepatic fibroinflammation involving transcriptional activation of ELR⁺ CXC chemokines

article Full Text OpenAlex

Cost-Effectiveness of Early vs Delayed Belimumab Treatment for Systemic Lupus Erythematosus

article Full Text OpenAlex

The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view

article Full Text OpenAlex

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimization

article Full Text OpenAlex

Dual roles of T cells in metabolic dysfunction–associated steatohepatitis pathogenesis and liver fibrosis: From inflammation to therapeutic targets

article Full Text OpenAlex

Longitudinal Changes in Cardiometabolic Risk Factors are Associated with Changes in Liver Stiffness in Adults with MASLD

article Full Text OpenAlex

Prevalence and risk factors for metabolic dysfunction–associated steatotic liver disease in Sweden: Insights from the SCAPIS cohort

article Full Text OpenAlex

Efficacy of combination therapy with lifestyle modification and ursodeoxycholic acid in patients with non-alcoholic fatty liver disease: Results of a prospective study

article Full Text OpenAlex

Overlapping Transcriptomic Features between Autoimmune Liver Disease and Chronic Hepatitis B Highlight Inflammatory Signatures as Focal Points of Liver Disease Progression and HCC-associated Mortality

article Full Text OpenAlex

近5年高被引文献
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

article Full Text OpenAlex 1461 FWCI580.1987

Hepatic inflammatory responses in liver fibrosis

review Full Text OpenAlex 600 FWCI130.4702

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

article Full Text OpenAlex 363 FWCI144.3538

EASL Clinical Practice Guidelines on sclerosing cholangitis

article Full Text OpenAlex 332 FWCI41.4249

Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease

review Full Text OpenAlex 322 FWCI47.8502

Challenges and opportunities in NASH drug development

review Full Text OpenAlex 318 FWCI71.6802

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

article Full Text OpenAlex 308 FWCI97.5211

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

article Full Text OpenAlex 305 FWCI65.8344

AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

article Full Text OpenAlex 295 FWCI57.5506

AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review

article Full Text OpenAlex 254 FWCI38.8101